Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

76.06USD
16 Nov 2018
Change (% chg)

$1.22 (+1.63%)
Prev Close
$74.84
Open
$74.71
Day's High
$76.25
Day's Low
$74.71
Volume
5,739,060
Avg. Vol
2,998,924
52-wk High
$76.25
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $194,014.09
Shares Outstanding(Mil.): 2,600.38
Dividend: 0.55
Yield (%): 2.95

Financials

  MRK.N Industry Sector
P/E (TTM): 33.83 28.12 29.34
EPS (TTM): 2.21 -- --
ROI: 8.65 14.10 13.58
ROE: 16.83 15.67 15.11

Merck drug Keytruda succeeds in late-stage esophageal cancer trial

Merck & Co's blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.

Nov 14 2018

UPDATE 1-Merck drug Keytruda succeeds in late-stage esophageal cancer trial

Nov 14 Merck & Co's blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.

Nov 14 2018

Merck cancer drug Keytruda succeeds in late-stage trial

Nov 14 U.S. drugmaker Merck & Co said on Wednesday its blockbuster cancer drug Keytruda met the main goal of a late-stage trial, of extending the lives of patients with cancers of the digestive tract.

Nov 14 2018

UPDATE 1-Roche's Tecentriq wins fast FDA review in tough-to-treat breast cancer

* Roche aiming to be first-to-market in niche areas (Adds comment from company, details about trial)

Nov 13 2018

Merck, Bristol-Myers profits rise on cancer drug sales

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

Oct 25 2018

WRAPUP 1-Merck, Bristol-Myers profits rise on cancer drug sales

Oct 25 Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

Oct 25 2018

Merck says to retain animal health business as part of company

Oct 25 Merck & Co Inc on Thursday indicated that it would keep its animal health business as part of the company, in response to questions about its plans for the unit.

Oct 25 2018

Cancer drug Keytruda powers Merck's profit beat, forecast raise

Merck & Co Inc said on Thursday sales of its blockbuster cancer immunotherapy Keytruda nearly doubled in the third quarter, helping the drugmaker beat profit estimates and lift its adjusted earnings forecast for the year.

Oct 25 2018

UPDATE 2-Cancer drug Keytruda powers Merck's profit beat, forecast raise

Oct 25 Merck & Co Inc said on Thursday sales of its blockbuster cancer immunotherapy Keytruda nearly doubled in the third quarter, helping the drugmaker beat profit estimates and lift its adjusted earnings forecast for the year.

Oct 25 2018

Merck reports third-quarter profit vs year-ago loss

Oct 25 Merck & Co Inc posted a third-quarter profit on Thursday, compared with a loss a year earlier, helped by strong demand for its blockbuster immunotherapy Keytruda and the drug's dominance as an initial treatment for advanced lung cancer.

Oct 25 2018

Earnings vs. Estimates